ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

ProteoTech Inc., is a private drug development Company founded in 1996 that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloidosis.

 

With over 165 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1® for the treatment of mild-to-moderate Alzheimer's disease.

 

The Company is in late stage pre-clinical development with Synuclere for the treatment of Parkinson's disease, and Systebryl for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere as a nasal spray for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes.

Recent Presentations
Exebryl-1 Pepticlere
ProteoTech International Alzheimer's
Conference Presentation - Exebryl-1®
ProteoTech International Alzheimer's
Conference Presentation - PeptiClere
ProteoTech's Disease Targets
ProteoTech's Alzheimers Target:Beta-amyloid Protein ProteoTech's Parkinson's Target:Alpha-synuclein
ProteoTech's Alzheimers Target: Beta-amyloid Protein ProteoTech's Parkinson's Target: Alpha-synuclein
Human Alzheimer's brain filled
with amyloid plaques (arrows)
(click image to enlarge)
Neuron in the substantia nigra with a Lewy
body containing alpha-synuclein
(click image to enlarge)
ProteoTech's Type 2 Diabetes Target:Islet Amyloid Polypeptide ProteoTech's Systemic AA Amyloidosis Target:Systemic AA Amyloidosis
ProteoTech's Type 2 Diabetes Target: Islet Amyloid Polypeptide ProteoTech's Systemic AA Amyloidosis Target: Systemic AA Amyloidosis
Congo red staining of IAPP amyloid
deposits in Islet of Langerhans
(pancreas) of patient with Type 2 Diabetes
(click image to enlarge)
Systemic AA amyloid deposits in liver
(click image to enlarge)
News

November 11, 2008
ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference

 

August 07, 2008
ProteoTech's Exebryl-1® Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

 

July 29, 2008
Exebryl-1® Phase I Human Clinical Trial for Alzheimer's disease commences

 

July 25, 2008
ProteoTech to present at International Alzheimer's Conference—Chicago, IL.

 

May 28, 2008
ProteoTech receives clearance from FDA to proceed with Phase I Human Clinical Trials for Exebryl-1®

 

May 15, 2008
ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

 

April 28, 2008
ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease